Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARSHALL PATRICK STAGG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841281573
CMS profile
356363
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,856.11

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,622.15 138
Long term medical supply or device loan $999.96 12
Education $234.00 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARSHALL PATRICK STAGG

NPI 1841281573 · CMS profile ID 356363

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $4,856.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–154 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $15.3901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101122452 CMS
Eisai Inc. $17.8401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110764027 CMS
AstraZeneca Pharmaceuticals LP $19.0601/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104767260 CMS
AstraZeneca Pharmaceuticals LP $17.1401/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105284573 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $765.06 15
PY2020 $735.60 13
PY2021 $33.73 2
PY2022 $2,463.58 111
PY2023 $3,267.62 128
PY2024 $4,856.11 154
PY2025 $6,615.18 154

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $490,331.12 32
PY2024 Principal investigator $759,128.66 38
PY2023 Principal investigator $301,996.27 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $72.00 12/31/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202418282
Principal investigator 1 Merck Sharp & Dohme LLC $36,291.31 12/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232923928
Principal investigator 1 Merck Sharp & Dohme LLC $102,712.11 12/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232923954
Principal investigator 1 Merck Sharp & Dohme LLC $36,032.31 12/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928269
Principal investigator 1 Merck Sharp & Dohme LLC $104,184.48 12/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928271
Principal investigator 1 Amgen Inc. $20,555.00 12/24/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246638102
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,350.00 12/10/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1236000392
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,188.42 11/19/2025 Non-covered Recipient Entity
Our Lady Of The Lake Rmc
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235994814
Principal investigator 1 Amgen Inc. $500.00 10/13/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246638106
Principal investigator 1 ABBVIE INC. $1,420.00 09/29/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202418265
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $1,333.75 09/04/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL No dispute reported 06/30/2026 1228756224
Principal investigator 1 ABBVIE INC. $1,400.00 08/19/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202418262
Principal investigator 1 ABBVIE INC. $1,000.00 08/05/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202418258
Principal investigator 1 ABBVIE INC. $1,000.00 07/31/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202418253
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $526.00 07/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL No dispute reported 06/30/2026 1228755369
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $745.00 07/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL No dispute reported 06/30/2026 1228755468
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $1,060.00 07/31/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL No dispute reported 06/30/2026 1228757540
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,305.00 07/25/2025 Non-covered Recipient Entity
OUR LADY OF THE LAKE PHYSICIAN GROUP
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190308544
Principal investigator 1 Celgene Corporation $24,356.59 06/25/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222304899
Principal investigator 1 Amgen Inc. $2,760.13 04/23/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246638104
Principal investigator 1 AstraZeneca Pharmaceuticals LP $158.65 04/09/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185541772
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,679.39 03/25/2025 Non-covered Recipient Entity
Our Lady Of The Lake Rmc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235994812
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,265.41 03/19/2025 Non-covered Recipient Entity
Our Lady Of The Lake Rmc
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235994816
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $858.21 03/17/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 1228746805
Principal investigator 1 Celgene Corporation $23,214.04 03/14/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222304933
Principal investigator 1 AstraZeneca UK Limited $17,131.35 03/11/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers No dispute reported 06/30/2026 1185541774
Principal investigator 1 PFIZER INC. $10,510.00 02/28/2025 Non-covered Recipient Entity
LSU Health Baton RougeNorth Clinic
A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 1228774827
Principal investigator 1 Amgen Inc. $24,605.54 02/22/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246638100
Principal investigator 1 Amgen Inc. $14,167.73 01/27/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Noninterventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced or Metastatic Malignancies No dispute reported 06/30/2026 1246638098
Principal investigator 1 Karyopharm Therapeutics Inc. $19,225.00 01/16/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246660751
Principal investigator 1 Karyopharm Therapeutics Inc. $1,440.00 01/16/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246660753
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,283.70 01/15/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185541770